검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 5개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap) Regeneron / Bayer·VEGF-A / VEGF-B / PIGF ORR 66.4% | voretigene neparvovec (Luxturna, AAV2-hRPE65v2, voretigene neparvovec-rzyl) Spark Therapeutics / Roche·RPE65 (AAV2) ORR null | |||
|---|---|---|---|---|---|
Overview Program | Lucentis (ranibizumab) | Eylea (aflibercept) | Luxturna (voretigene neparvovec) | Avastin | 4D-150 IVT |
Overview Company | Roche / Genentech | Regeneron / Bayer | Spark Therapeutics / Roche | Roche / Genentech | 4D Molecular Therapeutics |
Overview Modality | ANTIBODY | ANTIBODY | CGT | ANTIBODY | CGT |
Overview Target | VEGF-A | VEGF-A / VEGF-B / PIGF | RPE65 (AAV2) | Extranodal NK/T-cell Lymphoma, Nasal Typ | Diabetic Macular Edema |
Overview Indication | Wet AMD, DME, RVO, myopic CNV | Wet AMD, DME, RVO, diabetic retinopathy | Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations | Neovascular Age-Related Macular Degeneration | Neovascular (Wet) Age-Related Macular Degeneration |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_2 | PHASE_2 |
Overview Status | APPROVED | APPROVED | APPROVED | ACTIVE | RECRUITING |
MoA Mechanism | targeting angiopoietin-like protein 4 and vascular endothelial growth factor via neuropilin/RhoA signaling | inhibits its phosphorylation at Tyr42, promotes retention of the TGFβ receptor | AAV2-mediated RPE65 expression restores visual cycle isomerohydrolase activity in RPE | — | — |
MoA Biomarker | biomarker of treatment response, supporting further validation in larger independent cohorts | biomarkers can reliably diagnose and monitor PCV, restricting the role of invasive indocyanine green angiogra | MLMT score, full-field light sensitivity, BCVA | — | — |
PK/PD Half-life | 9 h | — | — | — | — |
PK/PD Species | Rat | Mouse, Pig | NHP, Despite these findings, and no systemic toxicity was identified., MLMT, FST | — | — |
PK/PD Animal (cat.) | Human, Rat | Mouse | NHP | — | — |
PK/PD Experiment | pharmacokinetic | Pharmacokinetic | biodistribution | — | — |
Toxicology Species | Rat | Mouse, Pig | NHP, Dog, Despite these findings, and no systemic toxicity was identified. | — | — |
Toxicology Animal (cat.) | Unknown | Unknown | NHP, Dog | — | — |
Toxicology Major finding | — | — | Procedure-related ocular AEs; inflammation manageable with steroids | thrombocytopenia, were frequently reported | — |
Clinical Primary efficacy | ORR 9.3% | ORR 66.4% | — | ORR 96% | — |
Clinical ORR | 9.3% | 66.4% | — | 96% | — |
Clinical PFS | — | — | Sustained functional vision gains | — | — |
Clinical Result source | ClinicalTrials.gov NCT03038880 | ClinicalTrials.gov NCT01958918 | Phase 3 / FDA label | ClinicalTrials.gov NCT00722865 | — |
Clinical Data Tier / Score | A · 69 | S · 87 | B · 54 | C · 53 | C · 14 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_2 | PHASE_2 |
Clinical Dose / schedule | — | — | One-time per eye (sequential) | — | — |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 12일 (1일 전) | 2026년 7월 6일 (8일 전) | 2026년 6월 1일 (43일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 5개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap) Regeneron / Bayer·VEGF-A / VEGF-B / PIGF ORR 66.4% | voretigene neparvovec (Luxturna, AAV2-hRPE65v2, voretigene neparvovec-rzyl) Spark Therapeutics / Roche·RPE65 (AAV2) ORR null | |||
|---|---|---|---|---|---|
Overview Program | Lucentis (ranibizumab) | Eylea (aflibercept) | Luxturna (voretigene neparvovec) | Avastin | 4D-150 IVT |
Overview Company | Roche / Genentech | Regeneron / Bayer | Spark Therapeutics / Roche | Roche / Genentech | 4D Molecular Therapeutics |
Overview Modality | ANTIBODY | ANTIBODY | CGT | ANTIBODY | CGT |
Overview Target | VEGF-A | VEGF-A / VEGF-B / PIGF | RPE65 (AAV2) | Extranodal NK/T-cell Lymphoma, Nasal Typ | Diabetic Macular Edema |
Overview Indication | Wet AMD, DME, RVO, myopic CNV | Wet AMD, DME, RVO, diabetic retinopathy | Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations | Neovascular Age-Related Macular Degeneration | Neovascular (Wet) Age-Related Macular Degeneration |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_2 | PHASE_2 |
Overview Status | APPROVED | APPROVED | APPROVED | ACTIVE | RECRUITING |
MoA Mechanism | targeting angiopoietin-like protein 4 and vascular endothelial growth factor via neuropilin/RhoA signaling | inhibits its phosphorylation at Tyr42, promotes retention of the TGFβ receptor | AAV2-mediated RPE65 expression restores visual cycle isomerohydrolase activity in RPE | — | — |
MoA Biomarker | biomarker of treatment response, supporting further validation in larger independent cohorts | biomarkers can reliably diagnose and monitor PCV, restricting the role of invasive indocyanine green angiogra | MLMT score, full-field light sensitivity, BCVA | — | — |
PK/PD Half-life | 9 h | — | — | — | — |
PK/PD Species | Rat | Mouse, Pig | NHP, Despite these findings, and no systemic toxicity was identified., MLMT, FST | — | — |
PK/PD Animal (cat.) | Human, Rat | Mouse | NHP | — | — |
PK/PD Experiment | pharmacokinetic | Pharmacokinetic | biodistribution | — | — |
Toxicology Species | Rat | Mouse, Pig | NHP, Dog, Despite these findings, and no systemic toxicity was identified. | — | — |
Toxicology Animal (cat.) | Unknown | Unknown | NHP, Dog | — | — |
Toxicology Major finding | — | — | Procedure-related ocular AEs; inflammation manageable with steroids | thrombocytopenia, were frequently reported | — |
Clinical Primary efficacy | ORR 9.3% | ORR 66.4% | — | ORR 96% | — |
Clinical ORR | 9.3% | 66.4% | — | 96% | — |
Clinical PFS | — | — | Sustained functional vision gains | — | — |
Clinical Result source | ClinicalTrials.gov NCT03038880 | ClinicalTrials.gov NCT01958918 | Phase 3 / FDA label | ClinicalTrials.gov NCT00722865 | — |
Clinical Data Tier / Score | A · 69 | S · 87 | B · 54 | C · 53 | C · 14 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_2 | PHASE_2 |
Clinical Dose / schedule | — | — | One-time per eye (sequential) | — | — |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 12일 (1일 전) | 2026년 7월 6일 (8일 전) | 2026년 6월 1일 (43일 전 · 갱신 권장) |
추천 비교
추천 비교